Gastroprotective effects of the insulin sensitizers rosiglitazone and metformin against indomethacin-induced gastric ulcers in Type 2 diabetic rats.
1. Gastric ulcers are common in Type 2 diabetic patients. Of all drugs used in the treatment of Type 2 diabetes, the insulin sensitizers thiazolidinediones (e.g. rosiglitazone) and metformin exhibit additional effects in ameliorating oxidative stress and inflammation, rendering them attractive candidates for the prevention of gastric ulcer in Type 2 diabetes. Thus, the aim of the present study was to evaluate the gastroprotective effects of rosiglitazone and metformin against indomethacin-induced gastric ulcer in Type 2 diabetic and non-diabetic rats. 2. Diabetes was induced by a single injection of streptozotocin (60 mg/kg, i.p., dissolved in 0.1 mol/L cold citrate buffer, pH 4.5), 15 min after administration of 120 mg/kg, i.p., nicotinamide. Three weeks after the successful induction of diabetes, rats were subjected to pyloric ligation and then injected immediately with 30 mg/kg, i.p., indomethacin. Three hours after indomethacin administration, rats were killed and gastric injury was evaluated. Ranitidine (50 mg/kg) was used as a reference drug and was administered in a single oral dose 1 h before indomethacin injection, as were rosiglitazone (3 mg/kg) and metformin (500 mg/kg). 3. Both rosiglitazone and metformin exhibited gastroprotective effects, as evidenced by significant decreases in the ulcer index, free and total acid output in gastric juice and gastric mucosal malondialdehyde concentrations, with concomitant increases in gastric juice pH (only with rosiglitazone), mucin concentrations, gastric mucosal concentrations of nitric oxide and catalase activity compared with untreated diabetic rats. Conversely, rosiglitazone and metformin had no effect on peptic activity and gastric mucosal prostaglandin E(2) content, particularly in the diabetic group, compared with the untreated groups. 4. In conclusion, rosiglitazone and metformin protect Type 2 diabetic rats against indomethacin-induced gastric ulceration, most possibly via antisecretory actions, enhanced mucosal protection and anti-oxidant activity. Rosiglitazone seems to be provide superior gastroprotection to metformin.
Morsy
Mohamed A
MA
Department of Pharmacology, Faculty of Medicine, El-Minia University, El-Minia, Egypt. mamm222@hotmail.com
Ashour
Osama M
OM
Fouad
Amr A
AA
Abdel-Gaber
Seham A
SA
D000818:Animals; D002374:Catalase / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D015232:Dinoprostone / Q000032:analysis; D005753:Gastric Mucosa / Q000187:drug effects; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D008315:Malondialdehyde / Q000032:analysis; D008687:Metformin / Q000627:therapeutic use*; D009077:Mucins / Q000187:drug effects; D009569:Nitric Oxide / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar; D000077154:Rosiglitazone; D013276:Stomach Ulcer / Q000209:etiology / Q000517:prevention & control*; D045162:Thiazolidinediones / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D009077:Mucins; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D009569:Nitric Oxide; D008315:Malondialdehyde; D008687:Metformin; D002374:Catalase; D015232:Dinoprostone; D007213:Indomethacin